CliffBio
biologic

Actemra

tocilizumab

Loss of exclusivityJanuary 2022projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand nameActemra
Active ingredienttocilizumab
Strength200MG/10ML (20MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalJanuary 2010
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Actemra patent cliff — loss of exclusivity January 2022 | CliffBio